针对乳腺癌治疗中的稳定剂及其类型的p53错误折叠难题:全面的计算分析
Burhan Ul Haq1, Hina Qayoom1, Shazia Sofi1
1Department of Bioresources, School of Biological Sciences, University of Kashmir, Srinagar, India.
Frontiers in pharmacology
|January 25, 2024
概括
这项研究探讨了PhiKan-083的研究.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 乳腺癌是女性最常见的癌症,三阴性乳腺癌 (TNBC) 特别具有攻击性.
- 在癌症中,p53通路经常失调,p53蛋白质的错误折叠和聚合有助于疾病的进展.
- 开发新的治疗方法来稳定p53和打击像TNBC这样的侵袭性癌症亚型至关重要.
研究的目的:
- 研究PhiKan-083及其类似物在稳定p53蛋白中的潜力.
- 探索p53相关癌症的新疗法策略,包括TNBC.
- 分析TP53在各种癌症中的表达模式和预后意义.
主要方法:
- 使用ADMET分析进行计算选.
- 分子对接以评估化合物-蛋白相互作用.
- 使用UALCAN,TIMER,GEPIA和PredictProtein数据库对TP53表达的生物信息分析.
主要成果:
- 识别具有潜在p53稳定性质的PhiKan-083类似物.
- 在药物相似性和结合相互作用的形评估.
- 分析TP53表达及其与多种癌症类型患者预后的相关性.
结论:
- 菲康-083类似物显示出作为稳定p53.3的潜在治疗剂的前景.
- 准p53聚合可能为治疗像TNBC这样的侵袭性癌症提供一种新的策略.
- 对这些化合物的进一步研究可以加速开发新的抗癌治疗方法.
相关概念视频
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Covalently Linked Protein Regulators
6.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.8K
DNA Damage can Stall the Cell Cycle
9.2K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.2K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


